Intravitreal injections of anti-vascular endothelial growth factor (VEGF) are commonly used to treat retinal diseases, as they allow the drug to act directly on the neovascular lesion and obtain better bioavailability through this delivery method (de Cogan et al., 2017). The gene discussed is VEGFA; the disease is Abnormal retinal morphology.